Showing Results for: “Contact ”

Safe at School: New Mexico

Safe at School: Utah

Safe at School: West Virginia

Discover practical tips and resources for school nurses to efficiently manage diabetes care in the school environment.

Make your time count by volunteering for one or more of the many ADA events. You'll make a difference through community outreach, advocacy, and inspiration.

Safe at School: Arkansas

Safe at School: District of Columbia

Safe at School: New Hampshire

The first sub-analysis of renal data from the Dapagliflozin Effect on Cardiovascular Events Thrombolysis In Myocardial Infarction (DECLARE-TIMI 58) trial indicates that dapagliflozin, an oral sodium glucose cotransporter 2 (SGLT2) inhibitor, reduced the progression of kidney disease or renal death in patients with type 2 diabetes (T2D). The initial results from the trial, the first cardiovascular outcome study to enroll a large cohort of patients with diabetes risk factors for Atherosclerotic Cardiovascular Disease (ASCVD) and a large number of patients with diabetes with known ASCVD, were

Results of the PIONEER 6 trial indicate oral semaglutide is safe for patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk, according to results announced at the symposium titled “Oral Semaglutide—The PIONEER Program Trials” today at the American Diabetes Association’s® (ADA) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. Oral semaglutide reduced cardiovascular death and all-cause mortality by nearly 50 percent, based on median follow up of 15.9 months. PIONEER 6 was conducted across 21 countries and included 3,183 participants who were randomized